Testing blood markers after a bone marrow donor transplant
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older).
- You have a blood cancer (a malignant hemopathy).
- Your doctors recommend an allogeneic bone marrow (stem cell) transplant from a donor.
- You agree to join the study by signing consent.
- You are covered by your local social security/health coverage plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well adults stay protected against measles after they receive a donor bone marrow transplant. It helps doctors understand measles immune status and may guide future protection for transplant recipients.
This study tests a new blood test to help predict whether acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will come back after a stem cell transplant. Early detection could help doctors treat relapse sooner.
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
This trial studies giving donor lymphocyte (immune) infusions after a bone marrow transplant for people with high-risk blood cancers. The goal is to help the immune system better fight the cancer and improve outcomes after transplant.
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
This study collects blood samples from patients who have survived at least 3 months after a stem cell transplant to identify markers that could predict chronic graft-versus-host disease (a condition where the transplanted cells attack the body). The goal is to develop a simple blood test that could help doctors catch and treat this complication earlier.
Hear when a new Malignant Hemopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.